RenovoRx's TIGeR-PaC Phase III Trial Surpasses 100 Patients, Nears Enrollment Completion
Summary
RenovoRx announced a significant milestone in its Phase III TIGeR-PaC clinical trial, surpassing 100 randomized patients. This progress keeps the study on track for enrollment completion in the first half of 2026, with final data anticipated in 2027. For a small-cap life sciences company, advancing a Phase III trial is a critical de-risking event, moving the company closer to potential commercialization of its novel drug-device combination for locally advanced pancreatic cancer. The independent data monitoring committee has twice recommended continuing the trial based on interim analyses, further bolstering confidence. This positive operational update follows recent financing activities, including a $10 million private placement, which likely supports the continued advancement of this trial. Investors will now watch for the official completion of enrollment and subsequent data readouts in 2027.
At the time of this announcement, RNXT was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.3M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.